Esophageal cancer is one of the most common malignancies of the digestive system with a high mortality rate and poor prognosis. It has been found to be the sixth leading cause of cancer-related deaths worldwide. This is due to the challenges associated with early detection due to the lack of specific symptoms, causing the majority of patients to be diagnosed at an advanced stage. The standard treatment for patients is concurrent chemoradiotherapy (CCRT) specifically from unresectable esophageal cancer patients. The 5-year survival rate for patients receiving CCRT has been found to be approximately 10-30%, primarily due to local tumor recurrence and distant metastasis. Therefore, further studies are required for the identification of diagnostic tools to improve the survival rate and prognosis of the disease.
Studies have shown drug therapy, specifically first and second generation platinum drugs including cisplatin, carboplatin, and nedaplatin, is commonly associated with drug resistance, nephrotoxicity and bone marrow suppression. Studies have investigated consolidation chemotherapy (CCT) following CCRT in esophageal cancer patients as CCT has been demonstrated to play a key role in various cancers. However, some studies found CCT prolonged the survival time of esophageal cancer patients while other studies found it had no influence on survival time or prognosis. Therefore, further studies are required to understand the impact of CCT in esophageal cancer patients.
The aim of this Research Topic is to explore the impact of chemotherapy in esophageal cancer and how it may influence the survival rate and prognosis. This Research Topic welcomes Original Research Article, Review Articles, Systematic Reviews and Mini Reviews.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Esophageal cancer is one of the most common malignancies of the digestive system with a high mortality rate and poor prognosis. It has been found to be the sixth leading cause of cancer-related deaths worldwide. This is due to the challenges associated with early detection due to the lack of specific symptoms, causing the majority of patients to be diagnosed at an advanced stage. The standard treatment for patients is concurrent chemoradiotherapy (CCRT) specifically from unresectable esophageal cancer patients. The 5-year survival rate for patients receiving CCRT has been found to be approximately 10-30%, primarily due to local tumor recurrence and distant metastasis. Therefore, further studies are required for the identification of diagnostic tools to improve the survival rate and prognosis of the disease.
Studies have shown drug therapy, specifically first and second generation platinum drugs including cisplatin, carboplatin, and nedaplatin, is commonly associated with drug resistance, nephrotoxicity and bone marrow suppression. Studies have investigated consolidation chemotherapy (CCT) following CCRT in esophageal cancer patients as CCT has been demonstrated to play a key role in various cancers. However, some studies found CCT prolonged the survival time of esophageal cancer patients while other studies found it had no influence on survival time or prognosis. Therefore, further studies are required to understand the impact of CCT in esophageal cancer patients.
The aim of this Research Topic is to explore the impact of chemotherapy in esophageal cancer and how it may influence the survival rate and prognosis. This Research Topic welcomes Original Research Article, Review Articles, Systematic Reviews and Mini Reviews.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.